The Global Tocilizumab Market size in 2023 is USD 81.19 million. The market share is projected to grow at a CAGR of 12.20% and reach USD 203.93 million by 2031.
Tocilizumab is a monoclonal antibody that targets interleukin-6 (IL-6) receptors. It treats various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, and cytokine release syndrome. Tocilizumab works by inhibiting IL-6, a cytokine involved in inflammatory processes, thus reducing inflammation and related symptoms. The global market for Tocilizumab is surging, fueled by its widening range of indications and rising need for precise treatments in inflammatory and autoimmune disorders. Initially authorized for rheumatoid arthritis (RA), Tocilizumab's applications have expanded to include juvenile idiopathic arthritis (JIA), giant cell arteritis (GCA), and cytokine release syndrome (CRS) related to CAR-T cell therapy.
Data Bridge Market Research Market Report provides details of new recent developments, market share, market trends on the basis of its segmentations and regional analysis, the impact of market players, analyses of opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market, contact Data Bridge Market Research’s team of expert analysts. Our team will help you make informed market decisions to achieve business growth.
Global Tocilizumab Market Analysis and Market Size
|
Global Tocilizumab Market Report Metric Details
|
|
|
|
Report Metric
|
Details
|
|
|
Forecast Period
|
2024-2031
|
|
|
Base Year
|
2023
|
|
|
Historic Year
|
2022 (Customizable 2016-2021)
|
|
|
Measuring Unit
|
USD Million
|
|
|
Data Pointers
|
Market value, growth rate, market segments, geographical coverage, market players, and market scenario, in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
|
Tocilizumab's ability to control intense inflammation and enhance patients' quality of life has significantly boosted its uptake. Moreover, its role in treating severe COVID-19 cases by addressing cytokine storms has expanded its market potential even further. As a result, Databridge Market Research dived into comprehensively analyzing the market and unveiled that the Global Phobic Disorders Treatment Market is increasing at a CAGR of 12.20%. Our detailed analysis forecasts that the market is valued at USD 81.19 Million in 2023 and is expected to grow up to USD 203.93 million by 2031. Our meticulously created report, developed through comprehensive research and analytics, is a distinguished paper that unveils eye-opening data about the market.
Global Tocilizumab Market Dynamics
Global Tocilizumab Market Growth Drivers
Expanding Indications for Autoimmune Diseases
Tocilizumab's market growth is significantly driven by its expanding approval for various autoimmune conditions. For instance, its recent approval for systemic sclerosis has opened new avenues in regions such as North America and Europe, where systemic sclerosis is prevalent. Such broader application enhances Tocilizumab's market potential and underscores its role in addressing unmet needs in autoimmune disease management.
Increased Use in COVID-19 Treatment
Tocilizumab's market growth has been notably accelerated by its effective role in managing severe COVID-19 cases, particularly through its action against cytokine release syndrome (CRS). For instance, in the United States, the FDA granted Emergency Use Authorization (EUA) for Tocilizumab to treat COVID-19-associated CRS in hospitalized patients, leading to its widespread use in clinical settings.
Global Tocilizumab Market Growth Opportunities
Emergence in Biosimilars
The emergence of Tocilizumab biosimilars, such as the FDA-approved Trazimera by Amgen, exemplifies a transformative growth opportunity in the market. This biosimilar offers a cost-effective alternative to the original drug, enhancing accessibility and affordability for patients, especially in price-sensitive markets. As patents for Tocilizumab expire, biosimilars like Trazimera are poised to broaden the drug's reach, making it more accessible to a larger patient population and driving significant Global Tocilizumab Market growth.
Global Tocilizumab Market Growth Challenges
Different treatment alternatives
While tocilizumab has shown effectiveness in treating autoimmune disorders, patients and healthcare providers have access to various other treatment options. Alternative biologic disease-modifying antirheumatic drugs (DMARDs), such as adalimumab and etanercept, are also widely used for managing conditions like rheumatoid arthritis consequently, hampering the overall Global Tocilizumab Market growth.
High cost of tocilizumab
The high cost of tocilizumab presents a significant barrier to its accessibility, especially in low- and middle-income countries. The drug's price, often exceeding thousands of dollars per treatment cycle, can be prohibitive for many patients, limiting widespread adoption. Cost-related challenge not only restricts patient access but also hampers the overall Global Tocilizumab Market growth in these economically constrained areas.
Global Tocilizumab Market Growth Restraints
Regulations restraining market expansion
Stringent approval processes and complex compliance requirements can delay market entry and limit the availability of tocilizumab in certain regions. For instance, in Brazil, ANVISA mandates that trials must be conducted within the country to assess the drug's safety and efficacy specifically in the Brazilian population. This regulation can significantly extend the timeline for drug approval and increase the associated costs, posing challenges for companies looking to introduce new biologics, consequently impeding the Global Tocilizumab Market Growth.
Global Tocilizumab Market Scope and Trends
|
Global Tocilizumab Market Segmentations Overview
|
|
|
Market
|
Sub-Segments
|
|
Product Type
|
Min Purity Less Than 98%, Min Purity 98%-99%, Min Purity More Than 99%
|
|
Application
|
Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), Rheumatoid Arthritis (RA)
|
|
Distribution Channel
|
Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
|
|
Route of Administration
|
Oral, Parenteral, Other
|
|
Demographic
|
Adult, Pediatric, Geriatric
|
|
End-Users
|
Clinic, Hospital, Others
|
|
Dosage
|
Injection, Solution, Concentrate
|
- TCZ-SC (subcutaneous) monotherapy demonstrated comparable efficacy and safety to TCZ-IV in patients with active RA who previously had an inadequate response to conventional DMARDs or biologics.
- The use of tocilizumab in combination with other agents, such as tocilizumab-methylprednisolone, to manage CRS more effectively and improve patient outcomes.
- Tocilizumab, when combined with a tapering course of glucocorticoids (or when administered alone following glucocorticoids), is indicated as an alternative for treating giant cell arteritis in people with relapsing or refractory illness. They have not already received tocilizumab.
Global Tocilizumab Market Regional Analysis – Market Trends
|
Global Tocilizumab Market Regional Overview
|
|
|
|
Region
|
Countries
|
|
|
Europe
|
Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe
|
|
|
APAC
|
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific
|
|
|
North America
|
U.S., Canada, and Mexico
|
|
|
MEA
|
Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East, and Africa
|
|
|
South America
|
Brazil, Argentina, and Rest of South America
|
|
Key Insights
- North America dominates the market, primarily due to its advanced healthcare infrastructure, high prevalence of autoimmune diseases, and favorable reimbursement policies. The United States, in particular, is a significant market, with extensive use of tocilizumab in both approved indications and off-label uses, such as in the treatment of severe COVID-19 case
- Europe with strong market presence driven by high awareness of autoimmune diseases and robust healthcare systems. Countries like Germany, France, and the United Kingdom are key contributors to the market, supported by widespread adoption of biologic therapies and government initiatives to support chronic disease management.
- The Asia-Pacific region is emerging as a fast-growing region, with increasing healthcare investments and rising incidence of autoimmune disorders. Japan and China are leading this growth, with Japan's well-established pharmaceutical industry and China's expanding biosimilar market playing crucial roles in driving market expansion.
- Brazil is emerging as a key player in Latin America's Tocilizumab market, driven by its expanding healthcare sector and increasing adoption of biologic therapies. The country’s public healthcare system, Sistema Único de Saúde (SUS), is working towards integrating biologics into its treatment protocols, which could significantly boost market growth.
Global Tocilizumab Market Leading Players
- Bio-Rad Laboratories, Inc. (U.S.)
- SimSon Pharma Limited (India)
- Selleck Chemicals (U.S.)
- Bio-Techne (U.S.)
- Biosynth (U.S)
- BioVision Inc.(U.S.)
- CLEARSYNTH LABS (U.S.)
- AbMole BioScience (U.S.)
- Biorbyt Ltd.(U.K.)
- Bloomberg Finance L.P. (U.S)
- LifeSpan BioSciences, Inc (U.S.)
Global Tocilizumab Market Recent Developments
- In June, 2024 Biogen Inc announced that the European Commission (EC) has approved TOFIDENCETM, a biosimilar monoclonal antibody based on ROACTEMRA. The European Commission has awarded TOFIDENCE's intravenous formulation marketing authorization for the treatment of moderate to severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19.
- In March, 2024, The FDA approved Tyenne, the second tocilizumab copycat overall and the first available in both intravenous and subcutaneous versions.
- In April, 2024 Biogen has announced that Tofidence (tocilizumab-bavi), a biosimilar to Roche's RoActemra, has been recommended by the European pharmaceuticals Agency's human pharmaceuticals committee to treat specific types of arthritis and COVID-19.
SKU-